{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T07:52:25Z","timestamp":1790409145728,"version":"4.1.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100015622","name":"Ministerul Cercet\u0103rii \u015fi Inov\u0103rii","doi-asserted-by":"publisher","award":["PNRR\/2022\/C9\/MCID\/18, Contract No. 760278\/26.03.2024"],"award-info":[{"award-number":["PNRR\/2022\/C9\/MCID\/18, Contract No. 760278\/26.03.2024"]}],"id":[{"id":"10.13039\/501100015622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015622","name":"Ministerul Cercet\u0103rii \u015fi Inov\u0103rii","doi-asserted-by":"publisher","award":["PNRR\/2022\/C9\/MCID\/18, Contract No. 760278\/26.03.2024"],"award-info":[{"award-number":["PNRR\/2022\/C9\/MCID\/18, Contract No. 760278\/26.03.2024"]}],"id":[{"id":"10.13039\/501100015622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015622","name":"Ministerul Cercet\u0103rii \u015fi Inov\u0103rii","doi-asserted-by":"publisher","award":["PNRR\/2022\/C9\/MCID\/18, Contract No. 760278\/26.03.2024"],"award-info":[{"award-number":["PNRR\/2022\/C9\/MCID\/18, Contract No. 760278\/26.03.2024"]}],"id":[{"id":"10.13039\/501100015622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015622","name":"Ministerul Cercet\u0103rii \u015fi Inov\u0103rii","doi-asserted-by":"publisher","award":["PNRR\/2022\/C9\/MCID\/18, Contract No. 760278\/26.03.2024"],"award-info":[{"award-number":["PNRR\/2022\/C9\/MCID\/18, Contract No. 760278\/26.03.2024"]}],"id":[{"id":"10.13039\/501100015622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015622","name":"Ministerul Cercet\u0103rii \u015fi Inov\u0103rii","doi-asserted-by":"publisher","award":["PNRR\/2022\/C9\/MCID\/18, Contract No. 760278\/26.03.2024"],"award-info":[{"award-number":["PNRR\/2022\/C9\/MCID\/18, Contract No. 760278\/26.03.2024"]}],"id":[{"id":"10.13039\/501100015622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015622","name":"Ministerul Cercet\u0103rii \u015fi Inov\u0103rii","doi-asserted-by":"publisher","award":["PNRR\/2022\/C9\/MCID\/18, Contract No. 760278\/26.03.2024"],"award-info":[{"award-number":["PNRR\/2022\/C9\/MCID\/18, Contract No. 760278\/26.03.2024"]}],"id":[{"id":"10.13039\/501100015622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015622","name":"Ministerul Cercet\u0103rii \u015fi Inov\u0103rii","doi-asserted-by":"publisher","award":["PNRR\/2022\/C9\/MCID\/18, Contract No. 760278\/26.03.2024"],"award-info":[{"award-number":["PNRR\/2022\/C9\/MCID\/18, Contract No. 760278\/26.03.2024"]}],"id":[{"id":"10.13039\/501100015622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015622","name":"Ministerul Cercet\u0103rii \u015fi Inov\u0103rii","doi-asserted-by":"publisher","award":["PNRR\/2022\/C9\/MCID\/18, Contract No. 760278\/26.03.2024"],"award-info":[{"award-number":["PNRR\/2022\/C9\/MCID\/18, Contract No. 760278\/26.03.2024"]}],"id":[{"id":"10.13039\/501100015622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015622","name":"Ministerul Cercet\u0103rii \u015fi Inov\u0103rii","doi-asserted-by":"publisher","award":["PNRR\/2022\/C9\/MCID\/18, Contract No. 760278\/26.03.2024"],"award-info":[{"award-number":["PNRR\/2022\/C9\/MCID\/18, Contract No. 760278\/26.03.2024"]}],"id":[{"id":"10.13039\/501100015622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015622","name":"Ministerul Cercet\u0103rii \u015fi Inov\u0103rii","doi-asserted-by":"publisher","award":["PNRR\/2022\/C9\/MCID\/18, Contract No. 760278\/26.03.2024"],"award-info":[{"award-number":["PNRR\/2022\/C9\/MCID\/18, Contract No. 760278\/26.03.2024"]}],"id":[{"id":"10.13039\/501100015622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015622","name":"Ministerul Cercet\u0103rii \u015fi Inov\u0103rii","doi-asserted-by":"publisher","award":["PNRR\/2022\/C9\/MCID\/18, Contract No. 760278\/26.03.2024"],"award-info":[{"award-number":["PNRR\/2022\/C9\/MCID\/18, Contract No. 760278\/26.03.2024"]}],"id":[{"id":"10.13039\/501100015622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008594","name":"European Hematology Association","doi-asserted-by":"publisher","award":["CAR NK cells for tumor associated macrophage immunomodulation\u2014a new era of immunotherapy"],"award-info":[{"award-number":["CAR NK cells for tumor associated macrophage immunomodulation\u2014a new era of immunotherapy"]}],"id":[{"id":"10.13039\/100008594","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008594","name":"European Hematology Association","doi-asserted-by":"publisher","award":["CAR NK cells for tumor associated macrophage immunomodulation\u2014a new era of immunotherapy"],"award-info":[{"award-number":["CAR NK cells for tumor associated macrophage immunomodulation\u2014a new era of immunotherapy"]}],"id":[{"id":"10.13039\/100008594","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008594","name":"European Hematology Association","doi-asserted-by":"publisher","award":["CAR NK cells for tumor associated macrophage immunomodulation\u2014a new era of immunotherapy"],"award-info":[{"award-number":["CAR NK cells for tumor associated macrophage immunomodulation\u2014a new era of immunotherapy"]}],"id":[{"id":"10.13039\/100008594","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008594","name":"European Hematology Association","doi-asserted-by":"publisher","award":["CAR NK cells for tumor associated macrophage immunomodulation\u2014a new era of immunotherapy"],"award-info":[{"award-number":["CAR NK cells for tumor associated macrophage immunomodulation\u2014a new era of immunotherapy"]}],"id":[{"id":"10.13039\/100008594","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008594","name":"European Hematology Association","doi-asserted-by":"publisher","award":["CAR NK cells for tumor associated macrophage immunomodulation\u2014a new era of immunotherapy"],"award-info":[{"award-number":["CAR NK cells for tumor associated macrophage immunomodulation\u2014a new era of immunotherapy"]}],"id":[{"id":"10.13039\/100008594","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008594","name":"European Hematology Association","doi-asserted-by":"publisher","award":["CAR NK cells for tumor associated macrophage immunomodulation\u2014a new era of immunotherapy"],"award-info":[{"award-number":["CAR NK cells for tumor associated macrophage immunomodulation\u2014a new era of immunotherapy"]}],"id":[{"id":"10.13039\/100008594","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003977","name":"Israel Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003977","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005984","name":"Dr. Miriam and Sheldon G. Adelson Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005984","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Professorship from the Israel Cancer Research Fund","award":["AC"],"award-info":[{"award-number":["AC"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biomark Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Multiple myeloma (MM) is a blood cancer characterized by the clonal evolution of plasma cells. In 2022, there were an estimated 118 000 MM cases and 121 000 deaths worldwide. The treatment landscape of MM has undergone a dramatic transformation in recent decades, shifting from conventional chemotherapy to more targeted approaches. In order to overcome intrinsic and acquired resistance mechanisms that frequently restrict the efficacy of single-agent therapies, drug combination strategies have been developed to simultaneously target multiple pathogenetic pathways. Building on the success of immunomodulatory agents, CRBN E3 ligase modulators (CELMoDs), iberdomide (CC-220) and mezigdomide (CC-92480), have been designed as promising and more selective agents. CELMoDs demonstrate a 10\u201320 times higher binding capacity and they promote a more profound and rapid breakdown of Ikaros and Aiolos compared to traditional immunomodulatory agents. According to the National Cancer Institute Surveillance Program, the median survival for fit patients is greater than ten years, and the 5-year survival for the general MM patient population in the US approaches 60%. Despite these encouraging numbers, MM is still an incurable disease, and the majority of patients eventually relapse and require additional lines of therapy. Combining CELMoDs with cellular therapies significantly improves the response rate in MM patients. In this paper, based on the literature presented at the Annual Meeting of the American Society of Hematology (ASH), the American Society of Clinical Oncology (ASCO), the International Myeloma Society (IMS), and the European Hematology Association (EHA) in the 2020\u20132025 timeframe, we explore the rationale and emerging evidence of combining CELMoDs with immunotherapies, and their use as a bridge to transplant or as post-ASCT maintenance therapy in MM.<\/jats:p>","DOI":"10.1186\/s40364-025-00825-8","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T13:16:55Z","timestamp":1755263815000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Targeting degradation of IKZF1 and IKZF3 through modulation of the E3 ligase substrates in the context of cellular therapies for multiple myeloma"],"prefix":"10.1186","volume":"13","author":[{"given":"David","family":"Kegyes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anamaria","family":"Bancos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian Bogdan","family":"Tigu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioana","family":"Rus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delia","family":"Dima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Cenariu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madalina","family":"Nistor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raluca","family":"Munteanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Gulei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Tanase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca","family":"Colita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca","family":"Buzoianu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Iuga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihnea","family":"Zdrenghea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan O.","family":"Ciurea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron","family":"Ciechanover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ciprian","family":"Tomuleasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,15]]},"reference":[{"key":"825_CR1","doi-asserted-by":"crossref","unstructured":"Mafra A, Laversanne M, Marcos-Gragera R, Chaves HVS, Mcshane C, Bray F et al. The global multiple myeloma incidence and mortality burden in 2022 and predictions for 2045. J Natl Cancer Inst. 2025;117(5):907\u2013914.","DOI":"10.1093\/jnci\/djae321"},{"issue":"8","key":"825_CR2","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/ajh.26590","volume":"97","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97(8):1086\u2013107.","journal-title":"Am J Hematol"},{"issue":"23","key":"825_CR3","doi-asserted-by":"publisher","first-page":"5993","DOI":"10.1182\/bloodadvances.2024014139","volume":"8","author":"MS Ebraheem","year":"2024","unstructured":"Ebraheem MS, Chakraborty R, Rochwerg B, Visram A, Mohyuddin GR, Venner CP, et al. Quadruplet regimens for patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis. Blood Adv. 2024;8(23):5993\u20136002.","journal-title":"Blood Adv"},{"issue":"3","key":"825_CR4","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1158\/2326-6066.CIR-20-0555","volume":"9","author":"D Mougiakakos","year":"2021","unstructured":"Mougiakakos D, Bach C, B\u00f6ttcher M, Beier F, R\u00f6hner L, Stoll A, et al. The IKZF1\u2013IRF4\/IRF5 axis controls polarization of myeloma-associated macrophages. Cancer Immunol Res. 2021;9(3):265\u201378.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"825_CR5","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/leu.2009.236","volume":"24","author":"H Quach","year":"2010","unstructured":"Quach H, Ritchie D, Stewart AK, Neeson P, Harrison S, Smyth MJ, et al. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2010;24(1):22\u201332.","journal-title":"Leukemia"},{"issue":"5971","key":"825_CR6","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1126\/science.1177319","volume":"327","author":"T Ito","year":"2010","unstructured":"Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, et al. Identification of a primary target of thalidomide teratogenicity. Science. 2010;327(5971):1345\u201350.","journal-title":"Science"},{"key":"825_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/5476903","volume":"2017","author":"Q Shi","year":"2017","unstructured":"Shi Q, Chen L, Cereblon. A protein crucial to the multiple functions of immunomodulatory drugs as well as cell metabolism and disease generation. J Immunol Res. 2017;2017:1\u20138.","journal-title":"J Immunol Res"},{"issue":"10","key":"825_CR8","doi-asserted-by":"publisher","first-page":"e354","DOI":"10.1038\/bcj.2015.66","volume":"5","author":"CC Bjorklund","year":"2015","unstructured":"Bjorklund CC, Lu L, Kang J, Hagner PR, Havens CG, Amatangelo M, et al. Rate of CRL4CRBN substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4. Blood Cancer J. 2015;5(10):e354\u2013354.","journal-title":"Blood Cancer J"},{"issue":"3","key":"825_CR9","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/j.1365-2141.2011.08689.x","volume":"154","author":"A Lopez-Girona","year":"2011","unstructured":"Lopez-Girona A, Heintel D, Zhang L, Mendy D, Gaidarova S, Brady H, et al. Lenalidomide downregulates the cell survival factor, interferon regulatory factor\u20104, providing a potential mechanistic link for predicting response. Br J Haematol. 2011;154(3):325\u201336.","journal-title":"Br J Haematol"},{"issue":"6","key":"825_CR10","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.3390\/cancers16061166","volume":"16","author":"MA Hartley-Brown","year":"2024","unstructured":"Hartley-Brown MA, Mo CC, Nadeem O, Midha S, Laubach JP, Richardson PG. Mezigdomide\u2014a novel cereblon E3 ligase modulator under investigation in relapsed\/refractory multiple myeloma. Cancers. 2024;16(6):1166.","journal-title":"Cancers"},{"key":"825_CR11","doi-asserted-by":"crossref","unstructured":"Shortt J. Mezigdomide and multiple myeloma. Phimister EG, editor. N Engl J Med. 2023;389(11):1046\u201350.","DOI":"10.1056\/NEJMe2307370"},{"issue":"8","key":"825_CR12","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1080\/17474086.2024.2382897","volume":"17","author":"Y Liu","year":"2024","unstructured":"Liu Y, Mo CC, Hartley-Brown MA, Sperling AS, Midha S, Yee AJ, et al. Targeting Ikaros and Aiolos: reviewing novel protein degraders for the treatment of multiple myeloma, with a focus on iberdomide and mezigdomide. Expert Rev Hematol. 2024;17(8):445\u201365.","journal-title":"Expert Rev Hematol"},{"issue":"1","key":"825_CR13","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13045-022-01296-2","volume":"15","author":"D Kegyes","year":"2022","unstructured":"Kegyes D, Constantinescu C, Vrancken L, Rasche L, Gregoire C, Tigu B, et al. Patient selection for CAR T or bite therapy in multiple myeloma: which treatment for each patient? J Hematol Oncol. 2022;15(1):78.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"825_CR14","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41420-024-01818-6","volume":"10","author":"L Xu","year":"2024","unstructured":"Xu L, Wen C, Xia J, Zhang H, Liang Y, Xu X. Targeted immunotherapy: harnessing the immune system to battle multiple myeloma. Cell Death Discov. 2024;10(1):55.","journal-title":"Cell Death Discov"},{"issue":"Supplement 1","key":"825_CR15","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1182\/blood-2018-99-113383","volume":"132","author":"M Amatangelo","year":"2018","unstructured":"Amatangelo M, Bjorklund CC, Kang J, Polonskaia A, Viswanatha S, Thakurta A. Iberdomide (CC-220) has synergistic anti-tumor and immunostimulatory activity against multiple myeloma in combination with both bortezomib and dexamethasone, or in combination with daratumumab in vitro. Blood. 2018;132(Supplement 1):1935\u20131935.","journal-title":"Blood"},{"issue":"15suppl","key":"825_CR16","doi-asserted-by":"publisher","first-page":"8006","DOI":"10.1200\/JCO.2019.37.15_suppl.8006","volume":"37","author":"S Lonial","year":"2019","unstructured":"Lonial S, Van De Donk NWCJ, Popat R, Zonder JA, Minnema MC, Larsen J, et al. First clinical (phase 1b\/2a) study of iberdomide (CC-220; IBER), a celmod, in combination with dexamethasone (DEX) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM). JCO. 2019;37(15suppl):8006\u20138006.","journal-title":"JCO"},{"issue":"11","key":"825_CR17","doi-asserted-by":"publisher","first-page":"e822","DOI":"10.1016\/S2352-3026(22)00290-3","volume":"9","author":"S Lonial","year":"2022","unstructured":"Lonial S, Popat R, Hulin C, Jagannath S, Oriol A, Richardson PG, et al. Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1\/2 trial. Lancet Haematol. 2022;9(11):e822\u201332.","journal-title":"Lancet Haematol"},{"issue":"4","key":"825_CR18","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/s41375-019-0620-8","volume":"34","author":"CC Bjorklund","year":"2020","unstructured":"Bjorklund CC, Kang J, Amatangelo M, Polonskaia A, Katz M, Chiu H, et al. Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN. Leukemia. 2020;34(4):1197\u2013201.","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"825_CR19","doi-asserted-by":"publisher","first-page":"3289","DOI":"10.1182\/blood-2023-189423","volume":"142","author":"P Ma","year":"2023","unstructured":"Ma P, Sridharan V, Wollerman K, Dutta D, Singh RK, Mukherjee S, et al. Iberdomide enhances Dara mediated cytotoxicity through upregulation of CDC activity and elevated NK cell mediated ADCC. Blood. 2023;142(Supplement 1):3289\u20133289.","journal-title":"Blood"},{"issue":"Supplement 1","key":"825_CR20","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1182\/blood-2024-199016","volume":"144","author":"M Amatangelo","year":"2024","unstructured":"Amatangelo M, Stong N, Maciag P, Sureda Balari A, Van De Donk NWCJ, Lonial S, et al. Iberdomide, daratumumab, and dexamethasone shows deep antimyeloma activity across molecular patient subsets with transplant-ineligible newly diagnosed multiple myeloma from the CC-220-MM-001 trial. Blood. 2024;144(Supplement 1):1973\u20131973.","journal-title":"Blood"},{"key":"825_CR21","doi-asserted-by":"publisher","first-page":"S9","DOI":"10.1016\/S2152-2650(21)02087-5","volume":"21","author":"S Lonial","year":"2021","unstructured":"Lonial S, Richardson PG, Popat R, Stadtmauer EA, Larsen JT, Oriol A, et al. OAB-013: iberdomide (IBER) in combination with dexamethasone (DEX) and daratumumab (DARA), bortezomib (BORT), or carfilzomib (CFZ) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM). Clin Lymphoma Myeloma Leuk. 2021;21:S9.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Supplement 1","key":"825_CR22","doi-asserted-by":"publisher","first-page":"4665","DOI":"10.1182\/blood-2023-178912","volume":"142","author":"M Amatangelo","year":"2023","unstructured":"Amatangelo M, Flynt E, Stong N, Ortiz M, Ray P, Wang M, et al. RRMM and post-BCMA treated subjects from the CC-220-MM-001 study show increased genomic aberrations associated with high-risk and significant dysfunction in CD4\u2009+\u2009T-cell compartment compared to NDMM subjects. Blood. 2023;142(Supplement 1):4665\u20134665.","journal-title":"Blood"},{"issue":"16suppl","key":"825_CR23","doi-asserted-by":"publisher","first-page":"TPS8069","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8069","volume":"41","author":"S Lonial","year":"2023","unstructured":"Lonial S, Quach H, Dimopoulos MA, Rodr\u00edguez-Otero P, Berdeja JG, Richardson PG, et al. EXCALIBER-RRMM: a phase 3, two-stage study of iberdomide, daratumumab, and dexamethasone (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM). JCO. 2023;41(16suppl):TPS8069\u20138069.","journal-title":"JCO"},{"key":"825_CR24","doi-asserted-by":"publisher","first-page":"153303382211065","DOI":"10.1177\/15330338221106563","volume":"21","author":"F Shen","year":"2022","unstructured":"Shen F, Shen W. Isatuximab in the treatment of multiple myeloma: a review and comparison with daratumumab. Technol Cancer Res Treat. 2022;21:15330338221106563.","journal-title":"Technol Cancer Res Treat"},{"issue":"Supplement 1","key":"825_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1182\/blood-2020-137667","volume":"136","author":"M Amatangelo","year":"2020","unstructured":"Amatangelo M, Bjorklund C, Ma P, Wollerman K, Pierceall W, Lonial S, et al. Preclinical and translational data support development of iberdomide in combination with CD38- and SLAMF7-directed monoclonal antibodies: evidence for rational combinations. Blood. 2020;136(Supplement 1):9\u201310.","journal-title":"Blood"},{"issue":"Supplement 1","key":"825_CR26","doi-asserted-by":"publisher","first-page":"4659","DOI":"10.1182\/blood-2023-174253","volume":"142","author":"J Eckmann","year":"2023","unstructured":"Eckmann J, Hage C, Stefanie L, Bayer C, Klein C, Umana P. Early intervention with celmods, but not imids, prevents relapse to forimtamig driven by GPRC5D-negative myeloma cells. Blood. 2023;142(Supplement 1):4659\u20134659.","journal-title":"Blood"},{"key":"825_CR27","doi-asserted-by":"publisher","first-page":"S131","DOI":"10.1016\/S2152-2650(23)01793-7","volume":"23","author":"A Aleman","year":"2023","unstructured":"Aleman A, Kogan-Zajdman A, Upadhyaya B, Van Oekelen O, Chen L, Leshchenko V, et al. P-175 improving anti-BCMA CAR-T functionality with novel immunomodulatory agent iberdomide (CC220) in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2023;23:S131\u20132.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6619","key":"825_CR28","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1126\/science.add7574","volume":"378","author":"ER Watson","year":"2022","unstructured":"Watson ER, Novick S, Matyskiela ME, Chamberlain PP, De La Pe\u00f1a H, Zhu A. Molecular glue celmod compounds are regulators of cereblon conformation. Science. 2022;378(6619):549\u201353.","journal-title":"Science"},{"key":"825_CR29","doi-asserted-by":"publisher","first-page":"100994","DOI":"10.1016\/j.blre.2022.100994","volume":"57","author":"O Fuchs","year":"2023","unstructured":"Fuchs O. Targeting cereblon in hematologic malignancies. Blood Rev. 2023;57:100994.","journal-title":"Blood Rev"},{"issue":"11","key":"825_CR30","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.clml.2024.06.004","volume":"24","author":"TH Patel","year":"2024","unstructured":"Patel TH, Van Rhee F, Al Hadidi S. Cereblon E3 ligase modulators mezigdomide and iberdomide in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2024;24(11):762\u20139.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"Supplement 1","key":"825_CR31","doi-asserted-by":"publisher","first-page":"3261","DOI":"10.1182\/blood-2024-199019","volume":"144","author":"TT Chow","year":"2024","unstructured":"Chow TT, Stong N, Tamim S, Bjorklund CC, Kurtova A, Desai K, et al. Biomarker analyses of the CC-92480-MM-001 trial to guide combinatorial strategies for mezigdomide. Blood. 2024;144(Supplement 1):3261\u20133261.","journal-title":"Blood"},{"issue":"Supplement 1","key":"825_CR32","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1182\/blood-2024-198403","volume":"144","author":"LJ Costa","year":"2024","unstructured":"Costa LJ, Schjesvold F, Popat R, Siegel D, Usmani SZ, Ali SA, et al. Mezigdomide (MEZI) in novel-novel combinations for relapsed or refractory multiple myeloma (RRMM): preliminary results from the CA057-003 trial. Blood. 2024;144(Supplement 1):677\u2013677.","journal-title":"Blood"},{"issue":"1","key":"825_CR33","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40364-018-0148-5","volume":"6","author":"R Tremblay-LeMay","year":"2018","unstructured":"Tremblay-LeMay R, Rastgoo N, Pourabdollah M, Chang H. EZH2 as a therapeutic target for multiple myeloma and other haematological malignancies. Biomark Res. 2018;6(1):34.","journal-title":"Biomark Res"},{"issue":"Supplement 1","key":"825_CR34","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1182\/blood-2024-203340","volume":"144","author":"S Martin","year":"2024","unstructured":"Martin S, Chrisochoidou Y, Margarido AS, Sialana F, Morales S, Leiro M, et al. IMiDs and celmods enhance antigen presentation via MHC class 1 - a potential novel immunostimulatory effect. Blood. 2024;144(Supplement 1):3284\u20133284.","journal-title":"Blood"},{"issue":"Supplement 1","key":"825_CR35","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1182\/blood-2023-189445","volume":"142","author":"H Chiu","year":"2023","unstructured":"Chiu H, Zhao J, Ortiz Estevez M, Hagner PR, Gandhi AK. Mezigdomide reverses T-cell exhaustion through degradation of aiolos\/ikaros and reinvigoration of cytokine production pathways. Blood. 2023;142(Supplement 1):335\u2013335.","journal-title":"Blood"},{"issue":"Supplement 1","key":"825_CR36","doi-asserted-by":"publisher","first-page":"4686","DOI":"10.1182\/blood-2023-187748","volume":"142","author":"LY Chen","year":"2023","unstructured":"Chen LY, Van Oekelen O, Amatangelo M, Chow TT, Upadhyaya B, Lagana A, et al. Mezigdomide treatment in relapsed-refractory myeloma patients shifts bone marrow NK and T cell populations from exhaustion to activation. Blood. 2023;142(Supplement 1):4686\u20134686.","journal-title":"Blood"},{"issue":"Supplement 1","key":"825_CR37","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1182\/blood-2024-212225","volume":"144","author":"EW Meermeier","year":"2024","unstructured":"Meermeier EW, Sharik M, Du M, Stein CK, Zhu YX, Shi CX, et al. Celmod-dexamethasone combination overcomes primary resistance to T cell engagers caused by high tumor burden in a human CRBN\u2009+\u2009Preclinical model of multiple myeloma. Blood. 2024;144(Supplement 1):356\u2013356.","journal-title":"Blood"},{"issue":"Supplement1","key":"825_CR38","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1182\/blood-2019-124345","volume":"134","author":"L Wong","year":"2019","unstructured":"Wong L, Narla RK, Leisten J, Bauer D, Groza M, Gaffney B, et al. CC-92480, a novel cereblon E3 ligase modulator, is synergistic with dexamethasone, bortezomib, and daratumumab in multiple myeloma. Blood. 2019;134(Supplement1):1815\u20131815.","journal-title":"Blood"},{"issue":"6","key":"825_CR39","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.molcel.2020.12.046","volume":"81","author":"M Heider","year":"2021","unstructured":"Heider M, Eichner R, Stroh J, Morath V, Kuisl A, Zecha J, et al. The imid target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma. Mol Cell. 2021;81(6):1170\u2013e118610.","journal-title":"Mol Cell"},{"key":"825_CR40","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1016\/S2152-2650(23)01616-6","volume":"23","author":"A Oriol","year":"2023","unstructured":"Oriol A, Sandhu I, Raab M, White D, LeBlanc R, Raje N, et al. OA-49 mezigdomide (MEZI) plus dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): results from the CC-92480-MM-002 trial. Clin Lymphoma Myeloma Leuk. 2023;23:S31.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"825_CR41","doi-asserted-by":"publisher","first-page":"S495","DOI":"10.1016\/S2152-2650(23)01446-5","volume":"23","author":"PG Richardson","year":"2023","unstructured":"Richardson PG, Badelita SN, Besemer B, Boudreault JS, Byun JM, Cerchione C, et al. MM-372 A phase III, two-stage, randomized study of mezigdomide, bortezomib, and dexamethasone (MeziVd) versus pomalidomide, bortezomib, and dexamethasone (PVd) in relapsed\/refractory multiple myeloma (RRMM): SUCCESSOR-1. Clin Lymphoma Myeloma Leuk. 2023;23:S495\u20136.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"20","key":"825_CR42","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1182\/blood-2018-05-850727","volume":"132","author":"PL Fedele","year":"2018","unstructured":"Fedele PL, Willis SN, Liao Y, Low MS, Rautela J, Segal DH, et al. IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos. Blood. 2018;132(20):2166\u201378.","journal-title":"Blood"},{"issue":"Supplement 1","key":"825_CR43","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.1182\/blood-2023-178881","volume":"142","author":"TT Chow","year":"2023","unstructured":"Chow TT, Amatangelo M, Ma P, Bjorklund CC, Wollerman K, Civardi T, et al. Preclinical and translational biomarker analyses to inform clinical development of mezigdomide (CC-92480) in combination with dexamethasone and daratumumab in multiple myeloma. Blood. 2023;142(Supplement 1):3318\u20133318.","journal-title":"Blood"},{"issue":"Supplement 1","key":"825_CR44","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1182\/blood-2023-174443","volume":"142","author":"PG Richardson","year":"2023","unstructured":"Richardson PG, Sandhu I, Hofmeister CC, Orlowski RZ, White D, Belotti A, et al. Mezigdomide (MEZI) plus dexamethasone (DEX) and daratumumab (DARA) or elotuzumab (ELO) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): results from the CC-92480-MM-002 trial. Blood. 2023;142(Supplement 1):1013\u20131013.","journal-title":"Blood"},{"issue":"Supplement 1","key":"825_CR45","doi-asserted-by":"publisher","first-page":"7070","DOI":"10.1182\/blood-2022-157927","volume":"140","author":"DV Jeyaraju","year":"2022","unstructured":"Jeyaraju DV, Alapa M, O\u2019Donohue A, La Motte-Mohs R, Boss IW, Hagner P, et al. Suppression of myeloid cell-derived proinflammatory cytokines with celmod agents: implications for CRS with T-cell engagers (TCEs). Blood. 2022;140(Supplement 1):7070\u20131.","journal-title":"Blood"},{"issue":"Supplement 1","key":"825_CR46","doi-asserted-by":"publisher","first-page":"7054","DOI":"10.1182\/blood-2022-157987","volume":"140","author":"B Paiva","year":"2022","unstructured":"Paiva B, Gaffney B, Burnett K, Castiglioni P, Angelo M, Pierce DW, et al. Synergistic antitumor activity of alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA 2\u2009+\u20091 T cell engager (TCE), and celmod agents in multiple myeloma (MM) preclinical models. Blood. 2022;140(Supplement 1):7054\u20135.","journal-title":"Blood"},{"key":"825_CR47","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.3389\/fimmu.2018.03171","volume":"9","author":"G Di Lullo","year":"2019","unstructured":"Di Lullo G, Marcatti M, Heltai S, Tresoldi C, Paganoni AM, Bordignon C, et al. Immunomodulatory drugs in the context of autologous hematopoietic stem cell transplantation associate with reduced pro-tumor T cell subsets in multiple myeloma. Front Immunol. 2019;9:3171.","journal-title":"Front Immunol"},{"issue":"Supplement 1","key":"825_CR48","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1182\/blood-2023-177564","volume":"142","author":"NWCJ Van De Donk","year":"2023","unstructured":"Van De Donk NWCJ, Touzeau C, Terpos E, Perrot A, Mina R, De Ruijter M, et al. Iberdomide maintenance after autologous stem-cell transplantation in newly diagnosed MM: first results of the phase 2 EMN26 study. Blood. 2023;142(Supplement 1):208\u2013208.","journal-title":"Blood"},{"key":"825_CR49","doi-asserted-by":"crossref","unstructured":"Touzeau C, Leleu X, Tiab M, Macro M, Perrot A, Gay J et al. Iberdomide, ixazomib and dexamethasone in elderly patients with multiple myeloma at first relapse. Br J Haematol. 2025;bjh.19978.","DOI":"10.1111\/bjh.19978"},{"key":"825_CR50","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.bbrc.2021.02.110","volume":"549","author":"M Zhao","year":"2021","unstructured":"Zhao M, Hu M, Chen Y, Liu H, Chen Y, Liu B, et al. Cereblon modulator CC-885 induces CRBN-dependent ubiquitination and degradation of CDK4 in multiple myeloma. Biochem Biophys Res Commun. 2021;549:150\u20136.","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Biomarker Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-025-00825-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40364-025-00825-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40364-025-00825-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T05:14:00Z","timestamp":1757394840000},"score":1,"resource":{"primary":{"URL":"https:\/\/biomarkerres.biomedcentral.com\/articles\/10.1186\/s40364-025-00825-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["825"],"URL":"https:\/\/doi.org\/10.1186\/s40364-025-00825-8","relation":{},"ISSN":["2050-7771"],"issn-type":[{"value":"2050-7771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,15]]},"assertion":[{"value":"2 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The manuscript respects all the legal and ethical requirements.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All authors have read and approved the manuscript and offer their full consent to publish it.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"105"}}